The induction of apoptosis by the proteasome inhibitors MG-132 and PS-341 (bortezomib, Velcade®) in primary chronic lymphocytic leukemia (CLL) cells and the Burkitt lymphoma cell line BJAB was associated with upregulation of TRAIL and its death receptors, DR4 and DR5, and decreased c-FLIP protein expression [179]. This evidence concerns the gene TNFRSF10A and B-cell chronic lymphocytic leukemia.